Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-414 plus radiotherapy and temozolomide in newly diagnosed EGFR-amplified glioblastoma
CTR20170455Phase 3Suspended
- Sponsor
- AbbVie Inc.
- Start
- Jul 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of depatuxizumab mafodotin in glioblastoma (GBM), Gliosarcoma (GS), sponsored by AbbVie Inc.. Started Jul 2017; status: suspended.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on CTR20170455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170455.